Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12061510 | 0.81 | ALDH1A1 (0.47) | ALDH1A1CYP1A2CYP2C9CYP2C19ADRA2A | |
| SCHEMBL6752425 | 0.81 | ALDH1A1 (0.47) | ALDH1A1CYP1A2CYP2C9CYP2C19ADRA2A | |
| SCHEMBL12061505 | 0.81 | ALDH1A1 (0.47) | ALDH1A1CYP1A2CYP2C9CYP2C19ADRA2A | |
| SCHEMBL11672371 | 0.80 | ALDH1A1 (0.54) | ALDH1A1CYP1A2CYP2C9CYP2C19ADRA2A | |
| SCHEMBL6248166 | 0.80 | ALDH1A1 (0.54) | ALDH1A1CYP1A2CYP2C9CYP2C19ADRA2A | |
| SCHEMBL5690850 | 0.80 | ALDH1A1 (0.46) | ALDH1A1CYP1A2CYP2C9CYP2C19ADRA2A | |
| SCHEMBL9572756 | 0.80 | AOC3 (0.47) | ALDH1A1CYP1A2CYP2C9CYP2C19AOC3 | |
| SCHEMBL10416031 | 0.79 | ALDH1A1 (0.52) | ALDH1A1CYP1A2CYP2C9CYP2C19ADRA2A | |
| SCHEMBL5692139 | 0.77 | ALDH1A1 (0.43) | ALDH1A1CYP1A2CYP2C9CYP2C19ADRA2A | |
| SCHEMBL6929498 | 0.77 | ALDH1A1 (0.43) | ALDH1A1CYP1A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2758051-B1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-04-11 | — | — | EP | claimed |
| US-9328099-B2 | Cyanomethylpyrazole carboxamides as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-03 | — | — | US | claimed |
| US-20140228348-A1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-08-14 | — | — | US | claimed |
| US-20240156792-A1 | COMBINATION THERAPY USING AZABICYCLO COMPOUND FOR CANCER | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-05-16 | — | — | US | disclosed |
| US-11918562-B2 | Combination therapy using azabicyclo compound for cancer | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-03-05 | — | — | US | disclosed |
| US-20220016090-A1 | COMBINATION THERAPY USING AZABICYCLO COMPOUND FOR CANCER | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-01-20 | — | — | US | disclosed |
| US-11166943-B2 | Combination therapy using azabicyclo compound for cancer | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-11-09 | — | — | US | disclosed |
| WO-2021024393-A1 | CANCER COMBINATION THERAPY USING AZABICYCLIC COMPOUND AND POLYADENOSINE-5'-DIPHOSPHATE RIBOSE POLYMERASE INHIBITOR | 大鵬薬品工業株式会社 | 2021-02-11 | — | — | WO | disclosed |
| WO-2021025065-A1 | COMBINATION THERAPY FOR CANCER USING AZABICYCLIC COMPOUND AND POLY(ADENOSINE 5'-DIPHOSPHATE-RIBOSE) POLYMERASE INHIBITOR | 大鵬薬品工業株式会社 | 2021-02-11 | — | — | WO | disclosed |
| US-10849886-B2 | Combination therapy using azabicyclo compound for cancer | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-01 | — | — | US | disclosed |
| CN-107531624-B | Pyrrolidine compounds | 住友化学株式会社 | 2020-10-02 | — | — | CN | disclosed |
| EP-1262966-A2 | Optical recording medium and novel azaporphyrin compound | Mitsui Chemicals, Inc. (JP) | 2002-12-04 | — | — | EP | disclosed |
| EP-1247655-A1 | OPTICAL RECORDING MEDIUM AND NOVEL AZAPORPHYRIN COMPOUNDS | Mitsui Chemicals, Inc. (JP) | 2002-10-09 | — | — | EP | disclosed |
| EP-1245571-A1 | BENZBISAZOLE COMPOUND AND OPTICAL RECORDING MEDIUM CONTAINING THE COMPOUND | Mitsui Chemicals, Inc. (JP) | 2002-10-02 | — | — | EP | disclosed |
| EP-1180765-A1 | Optical recording medium and porphycene compound | Mitsui Chemicals, Inc. (JP) | 2002-02-20 | — | — | EP | disclosed |
| CN-1081676-A | The indoles and the indazole derivatives that are used for the treatment and the prevention of cerebral disorders, their preparation and application | SANKYO CO (JP) | 1994-02-09 | — | — | CN | disclosed |
| EP-0562832-A1 | Indole and indazole derivatives, for the treatment and prophylaxis of cerebral disorders, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1993-09-29 | — | — | EP | disclosed |
| US-4749691-A | Peptide, process for preparation thereof and use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-06-07 | — | — | US | disclosed |
| US-4057550-A | 14,15-DIHYDRO-14-CYANO-EBURNAMENINES, VASODILATION | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1977-11-08 | — | — | US | disclosed |
| US-4054571-A | Nitrogen-containing polycyclic compounds and a process for the preparation thereof | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1977-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156792-A1 | COMBINATION THERAPY USING AZABICYCLO COMPOUND FOR CANCER | HSP90AB1, HSP90AA1, HSP90AB2P | ALDH1A1 1356/4885CYP1A2 3901/4885CYP2C9 4168/4885 |
| US-20140228348-A1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | JAK1, JAK2, JAK3 | ALDH1A1 1995/4885CYP1A2 666/4885CYP2C9 473/4885 |
| US-11918562-B2 | Combination therapy using azabicyclo compound for cancer | HSP90AB1, HSP90AA1, HSP90AB2P | ALDH1A1 1356/4885CYP1A2 3901/4885CYP2C9 4168/4885 |
| US-10849886-B2 | Combination therapy using azabicyclo compound for cancer | HSP90AB1, HSP90AA1, HSP90AB2P | ALDH1A1 1356/4885CYP1A2 3901/4885CYP2C9 4168/4885 |
| US-20220016090-A1 | COMBINATION THERAPY USING AZABICYCLO COMPOUND FOR CANCER | HSP90AB1, HSP90AA1, HSP90AB2P | ALDH1A1 1356/4885CYP1A2 3901/4885CYP2C9 4168/4885 |
| US-11166943-B2 | Combination therapy using azabicyclo compound for cancer | HSP90AB1, HSP90AA1, HSP90AB2P | ALDH1A1 1356/4885CYP1A2 3901/4885CYP2C9 4168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.